[ad_1]
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (Globe Newswire) — Vaxart, Inc. (Nasdaq: VXRT) announced today that Founder and Chief Scientific Officer Dr. Sean Tucker will be speaking at the Global Vaccine Conference in Washington. I announced that I will be speaking at Conference 2024. Wednesday, April 3, 2024, Washington, DC. We have repeatedly performed at the annual event in Washington, DC.
Presentation information:
title: Moving the needle: Stopping infections with oral pill vaccination and boosting existing vaccines
speaker: Dr. Sean Tucker
date: Wednesday, April 3, 2024
time: 3:10pm ET
room: 207A
About Bakart
Vaxart is a clinical-stage biotechnology company developing a variety of oral recombinant vaccines based on proprietary delivery platforms. The Vaxart vaccine is designed to be administered using tablets that can be stored and transported without refrigeration and eliminate the risk of needle stick injuries. Vaxart believes its proprietary pill vaccine delivery platform is well-suited for the delivery of recombinant vaccines, and the company will develop oral versions of currently commercially available vaccines and develop recombinant vaccines for new indications. We are in a position to design. Vaxart’s development programs currently include tablet vaccines designed to protect against coronaviruses, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication. It is. Vaxart has extensive domestic and international patent applications covering proprietary technology and products for oral vaccination using adenoviruses and his TLR3 agonists.
contact address
|
Vaxart Media Relations: |
Public relations activities for investors: |
|
Mark Herr |
Andrew Brazier |
|
Bakart Co., Ltd. |
FINN Partner |
|
mherr@vaxart.com |
IR@Vaxart.com |
|
(203) 517-8957 |
(646) 871-8486 |
[ad_2]
Source link
